Ripretinib is primarily used in the treatment of gastrointestinal stromal tumors (GISTs), a type of cancer that originates in the digestive tract. It is specifically designed for patients who have previously received other treatments, such as imatinib, sunitinib, and regorafenib, but have experienced disease progression or intolerance. The drug works by inhibiting a broad range of mutant forms of KIT and PDGFRA kinases, which are often responsible for the growth and spread of GISTs. This targeted approach helps to slow down or stop the progression of the disease, offering a therapeutic option for patients with advanced or resistant forms of GIST. Ripretinib is typically administered orally, making it convenient for patients to use as part of their ongoing treatment regimen. Its ability to target multiple mutations in KIT and PDGFRA makes it a versatile option in the management of GISTs, particularly in cases where other therapies have failed. Clinical trials have demonstrated its efficacy in improving progression-free survival, making it a valuable addition to the arsenal of treatments available for this challenging cancer.